Sort
8,912 grants matching “sars cov 2”
EAGER: MEMS Enabled Real Time Detection of Pathogens Viruses and Biomarkers
$299,987Borislav L Ivanov · Vanderbilt University · · FY2022 · MPS
Development of Inhibitors Against SARS CoV-2 NSP16 Methyltransferase
$299,985Hongmin Li · Lychee Bioscience Llc · R41 · FY2025 · AI
Development of Inhibitors Against SARS CoV-2 NSP16 Methyltransferase
$299,985Hongmin Li · Lychee Bioscience Llc · R41 · FY2024 · AI
PA21259, SBIR Phase I, Developing a RIG-I agonist to prevent COVID-19
$299,984Bryan Berube · Hdt Bio Corporation · R43 · FY2022 · IP
Role of Endothelial eNAMPT/NAMPT secretion and TLR4 signaling in the ARDS Vascular Endotype
$299,983Joe G. N. Garcia · University Of Florida · P01 · FY2025 · HL
Memory-promoting Ad vaccine for long-lived protection against SARS-CoV-2
$299,983Dennis J Hartigan-O'Connor · Tendel Therapies Inc. · R41 · FY2021 · AI
Multiplexed CRISPR-based immune cell RNA profiling by flow and mass cytometry
$299,978Mitchell O'Connell · Dahlia Biosciences, Inc. · R41 · FY2021 · AI
Development of a Pan-COVID-19 Vaccine Candidate
$299,967Haitao Hu · Rna Therapeutics Inc. · R41 · FY2024 · AI
LA CaTS Supplement NOT-OD-21-101
$299,963John P. Kirwan · Lsu Pennington Biomedical Research Ctr · U54 · FY2021 · GM
EAGER: Rapid Planar PCR for COVID-19 Testing
$299,960Gregory W Faris · Sri International · · FY2020 · ENG
LARGE SCALE T CELL EPITOPE DISCOVERY - COVID Supplement
$299,928Stephen Wilson · La Jolla Institute For Immunology · N01 · FY2021 · AI
Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19
$299,927Mark Newman · Geovax, Inc. · R43 · FY2021 · AI
A Novel Broad-spectrum Antiviral Agent
$299,916Joana M Murad · Celdara Medical, Llc · R41 · FY2021 · AI
mTOR Regulation of Basal Antiviral Immunity in the Elderly
$299,903Joan Mannick · Tornado Therapeutics, Inc. · R01 · FY2023 · AG
A biophysical assay targeting SARS CoV-2 RNA
$299,900Sandra Paige Story · Nubad, Llc · R43 · FY2022 · AI
Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury
$299,894Edward Gomperts · Hillhurst Biopharmaceuticals, Inc. · R41 · FY2023 · AI
Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury
$299,894Edward Gomperts · Hillhurst Biopharmaceuticals, Inc. · R41 · FY2022 · AI
Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches
$299,878Karen G. Anthony · L2 Diagnostics, Llc · R41 · FY2024 · AI
Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches
$299,862Karen G. Anthony · L2 Diagnostics, Llc · R41 · FY2025 · AI
Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide
$299,860Jim Rotolo · Sapience Therapeutics, Inc. · R43 · FY2021 · AI
West Virginia Clinical and Translational Science Institute: A Statewide Organization Building Research Excellence and Engaging Communities to Improve Health
$299,858Sally Lynn Hodder · West Virginia University · U54 · FY2024 · GM
Lung delivery of novel ACE2 variants for COVID-19
$299,842Jack Henkin · Angiotensin Therapeutics, Inc. · R43 · FY2022 · HL
COVID-19 Vaccine and Menstrual Health in Adolescents
$299,744Laura A Payne · Mclean Hospital · R01 · FY2021 · HD
Microbiology and Immunology Training for HIV and HIV-Related Research in Uganda (MITHU)
$299,645W. Henry Henry Boom · Case Western Reserve University · D43 · FY2021 · TW
EAGER: Structural Basis for Assembly and Replication of Coronavirus
$299,577Katherine A Henzler-Wildman · University Of Wisconsin-Madison · · FY2020 · BIO